熱門資訊> 正文

Mereo BioPharma与私人控股的âshibio签署许可协议

2025-08-19 21:43

Mereo BioPharma (NASDAQ:MREO) signed an exclusive licensing deal with privately held biotech āshibio, for the antibody therapy vantictumab, intended to treat autosomal dominant osteopetrosis type 2.
According to the deal, āshibio will take charge of the global clinical development of vantictumab for both adult and pediatric patients.
āshibio will have exclusive rights to develop and market vantictumab in the U.S. and other regions worldwide, except for Europe, where Mereo will maintain its commercial rights.

More on Mereo BioPharma Group

Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI
Ultragenyx, Mereo in selloff after trial update on bone disorder therapy
Seeking Alpha’s Quant Rating on Mereo BioPharma Group
Historical earnings data for Mereo BioPharma Group
Financial information for Mereo BioPharma Group

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。